Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aptorum Group Limited (APM)
London, GB
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +22.90% | +28.80% | +17.71% | +32.00% | -23.70% | -2.83% | +11.96% | -66.77% | -96.41% | -99.28% | -99.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+75.6% ★ Q4'25: -125.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-13.2% ★ Q4'25: -41.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+34.8% Q4'25: +41.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.94× Q4'25: -0.62× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
383.5K
est: 380.0K (+0.9%)
|
535.2K
est: 900.0K (-40.5%)
|
911.5K
est: 700.0K (+30.2%)
|
1.54M
est: 1.30M (+18.6%)
|
1.30M
est: 1.30M (-0.3%)
|
431.4K
est: 2.30M (-81.2%)
|
—
est: 31.20M (-100.0%)
|
—
est: 65.70M (-100.0%)
|
106.80M
106.80M – 106.80M
+62.6% YoY
|
| EBITDA |
-9.99M
est: -76.0K (-13,050.2%)
|
-15.12M
est: -180.0K (-8,298.9%)
|
6.50M
est: -140.0K (+4,741.5%)
|
-25.83M
est: -260.0K (-9,833.9%)
|
-10.32M
est: -260.0K (-3,868.3%)
|
-9.48M
est: -460.0K (-1,960.1%)
|
-3.76M
est: -6.24M (+39.8%)
|
-1.82M
est: -13.14M (+86.2%)
|
-21.36M
-21.36M – -21.36M
-62.6% YoY
|
| EBIT |
-10.68M
est: -76.0K (-13,947.6%)
|
-16.42M
est: -180.0K (-9,020.6%)
|
5.16M
est: -140.0K (+3,788.6%)
|
-27.02M
est: -260.0K (-10,292.7%)
|
-11.53M
est: -260.0K (-4,332.7%)
|
-10.60M
est: -460.0K (-2,204.6%)
|
-4.01M
est: -6.24M (+35.7%)
|
-1.82M
est: -13.14M (+86.2%)
|
-21.36M
-21.36M – -21.36M
-62.6% YoY
|
| Net Income |
-14.83M
est: -27.65M (+46.4%)
|
-18.69M
est: -28.36M (+34.1%)
|
7.07M
est: -33.26M (+121.2%)
|
-25.05M
est: -43.62M (+42.6%)
|
-9.80M
est: -16.90M (+42.0%)
|
-2.83M
est: -28.90M (+90.2%)
|
-4.27M
est: -5.15M (+17.1%)
|
-1.36M
est: 8.09M (-116.9%)
|
22.79M
22.79M – 22.79M
+181.8% YoY
|
| SGA |
6.73M
est: 2.36M (+185.3%)
|
10.78M
est: 5.59M (+92.9%)
|
7.71M
est: 4.35M (+77.4%)
|
8.03M
est: 8.07M (-0.5%)
|
7.97M
est: 8.07M (-1.3%)
|
4.42M
est: 14.28M (-69.1%)
|
1.47M
est: 147.18M (-99.0%)
|
1.64M
est: 309.92M (-99.5%)
|
503.80M
503.80M – 503.80M
+62.6% YoY
|
| EPS |
-5.31
est: -5.07 (-4.7%)
|
-6.40
est: -5.20 (-23.1%)
|
2.03
est: -6.10 (+133.3%)
|
-7.15
est: -8.00 (+10.6%)
|
-2.75
est: -3.10 (+11.3%)
|
-0.62
est: -5.30 (+88.3%)
|
-0.78
est: -0.70 (-11.4%)
|
-0.19
est: 1.10 (-117.3%)
|
3.10
3.10 – 3.10
+181.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | s: Ian Huen (“Ian”) | 164.91M | 69.25% | — | — | — | — | IN | or Place of Organization: | 2021-06-01 | ↗ |
| 2 | s: Jurchen Investment Corporation (“Jurchen”) | 164.86M | 69.24% | — | — | — | — | CO | or Place of Organization: | 2021-06-01 | ↗ |
| 3 | CGY Investments Limited (“CGY | 40.63M | 17.59% | — | 40.63M | — | 40.63M | CO | Hong Kong | 2019-07-11 | ↗ |
| 4 | s: CGY Investments Limited (“CGY Investments”) | 40.63M | 17.59% | — | — | — | — | CO | or Place of Organization: | 2019-05-08 | ↗ |
| 5 | Darren Lui (“Darren”) | 24.89M | 10.78% | — | — | — | — | IN | Citizenship or Place of Organization: | 2019-05-08 | ↗ |
| 6 | Darren Lui (“Darren” | 21.66M | 9.38% | — | 21.66M | — | 21.66M | IN | Hong Kong | 2019-07-11 | ↗ |
| 7 | s: Seng Fun Yee (“Seng Fun”) | 20.31M | 8.80% | — | — | — | — | IN | Citizenship or Place of Organization: | 2019-05-08 | ↗ |
| 8 | Seng Fun Yee (“Seng Fun”) | 20.31M | 8.79% | — | 20.31M | — | 20.31M | IN | Malaysia | 2019-07-11 | ↗ |
| 9 | s: Sui Fong Isabel Huen Ng (“Isabel”) | 19.29M | 8.35% | — | — | — | — | IN | Citizenship or Place of Organization: | 2019-05-08 | ↗ |
| 10 | Hudson Bay Capital Management LP | 923.1K | 6.54% | — | 923.1K | — | — | PN | State of Delaware | 2022-02-07 | ↗ |
| 11 | Sander Gerber | 923.1K | 6.54% | — | 923.1K | — | — | IN | United States | 2022-02-07 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kwok Kuen Wong | Head of Finance | 92.3K | male |
| Chung Yuen Huen | Founder, Chief Executive Officer & Executive Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
